Anika Therapeutics Inc (ANIK) 41.47 $ANIK
Global Anti-Adhesion Products - Strategic Business Report 2014
M2 - Mon Aug 18, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msqpk/antiadhesion) has announced the addition of the "Anti-Adhesion Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as: - Anika Therapeutics, Inc. - Baxter Healthcare Ltd. - Covidien - Ethicon, Inc. - FzioMed, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study - Adhesion - Anti-Adhesion Products - General/Abdominal Surgery - Pelvic/Gynecological Surgery - Other Surgical Procedures II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. ADVANCED WOUND CARE TECHNOLOGIES AN OVERVIEW OF THE LARGER MARKET 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 19 (including Divisions/Subsidiaries 22) - The United States (9) - Japan (1) - Europe (11) - Germany (2) - The United Kingdom (3) - Rest of Europe (6) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/9m...tiadhesion
Regenerative Medicine Market 2014-2020 - Global Strategic Business Report
M2 - Thu Aug 14, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwcn7x/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 46 companies including many key and niche players such as: - AlloSource - Anika Therapeutics, Inc. - Biomet, Inc. - Bioventus LLC - DePuy Synthes Companies Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Regenerative Medicine A Macro Perspective 3. Bone And Joint Regenerative Medicine An Overview 4. Competitive Landscape 5. Regenerative Medicine In Other Areas 6. Regulatory Environment 7. A Peek Into The Global Orthopedic Industry 8. Research And Development 9. Product Overview 10. Product Innovations/Introductions 11. Recent Industry Activity 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Asia-Pacific 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 46 (including Divisions/Subsidiaries 51) - The United States (38) - Europe (11) - Germany (2) - The United Kingdom (2) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/jw...generative
Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis to 2019 for the $6.4 Billion Industry
M2 - Mon Aug 11, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sb3q8w/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019. The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period. In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019. The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Regenerative Medicine (Bone and Joint) Market, by Technology Chapter 5 Regenerative Medicine (Bone and Joint) Market, by Applications Chapter 6 Regenerative Medicine (Bone and Joint) Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Anika Therapeutics, Inc. - Arthrex, Inc. - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew plc - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sb...generative
Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
Business Wire - Mon Aug 04, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 10:30 a.m. ET. The conference is being held at the InterContinental Hotel in Boston, Massachusetts.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIKA THERAPEUTICS
at Investor's Business Daily - Wed Jul 30, 6:03PM CDT
ANIKA THERAPEUTICS (ANIK), a bone-healing product maker, said Q2 EPS rose 50% to 60 cents, beating by 3 cents. Sales increased 26% to $26.3 mil, but missed views for $28.2 mil. Shares fell 6.5% to 46.50.
Anika Therapeutics Reports Second-Quarter 2014 Financial Results
Business Wire - Wed Jul 30, 3:05PM CDT
--Commercial Launch of Monovisc(R) Generates $5 Million Milestone Payment
Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix(R) with Wound Care Leader Medline Industries, Inc.
Business Wire - Wed Jul 30, 12:04PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company's advanced wound care product - Hyalomatrix(R), in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix(R) is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.
Anika Therapeutics Up 36.4% Since SmarTrend Uptrend Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 28, 5:06PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.67. In approximately 5 months, Anika Therapeutics has returned 36.35% as of today's recent price of $47.28.
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019
M2 - Mon Jul 21, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ct2qw/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019" report to their offering. Hyaluronic acid (HA) is a glycosaminoglycan that helps in transportation of nutrients through the body and facilitate water retention in body tissue. It is naturally found in body - in joints, eye cavity, immune system and others. HA was observed to be an important component of articular cartilage where it is present in the form of a coat around each chondrocyte. This report studies the global hyaluronic acid products market by types of products, applications and the major geographic markets. Products market is segmented as single-injection, three-injection cycle and five-injection cycle. Similarly, applications market is segmented as osteoarthritis, ophthalmic surgery, dermal fillers and vesicoureteral reflux (VUR). The market overview section of the hyaluronic acid products market report discusses the market dynamics with respect to market drivers, restraints and opportunities. This section also covers market attractiveness analysis (by geography) and Porter's five forces analysis for the global hyaluronic acid products market. Market share (%) for the major players operating in this market has also been provided for the year 2012, followed by a list of recommendations for the existing and new players to enter and enhance their market shares. The report concludes with the company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. The global hyaluronic acid products market is segmented as follows: Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Hyaluronic Acid Products Market, by Products Chapter 5 Global Hyaluronic Acid Products Market, by Applications Chapter 6 Global Hyaluronic Acid Products Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/6c...ronic_acid
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
Global Anti-Adhesion Products - Strategic Business Report 2014
M2 - Mon Aug 18, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msqpk/antiadhesion) has announced the addition of the "Anti-Adhesion Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as: - Anika Therapeutics, Inc. - Baxter Healthcare Ltd. - Covidien - Ethicon, Inc. - FzioMed, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study - Adhesion - Anti-Adhesion Products - General/Abdominal Surgery - Pelvic/Gynecological Surgery - Other Surgical Procedures II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. ADVANCED WOUND CARE TECHNOLOGIES AN OVERVIEW OF THE LARGER MARKET 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 19 (including Divisions/Subsidiaries 22) - The United States (9) - Japan (1) - Europe (11) - Germany (2) - The United Kingdom (3) - Rest of Europe (6) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/9m...tiadhesion
Regenerative Medicine Market 2014-2020 - Global Strategic Business Report
M2 - Thu Aug 14, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwcn7x/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 46 companies including many key and niche players such as: - AlloSource - Anika Therapeutics, Inc. - Biomet, Inc. - Bioventus LLC - DePuy Synthes Companies Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Regenerative Medicine A Macro Perspective 3. Bone And Joint Regenerative Medicine An Overview 4. Competitive Landscape 5. Regenerative Medicine In Other Areas 6. Regulatory Environment 7. A Peek Into The Global Orthopedic Industry 8. Research And Development 9. Product Overview 10. Product Innovations/Introductions 11. Recent Industry Activity 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Asia-Pacific 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 46 (including Divisions/Subsidiaries 51) - The United States (38) - Europe (11) - Germany (2) - The United Kingdom (2) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/jw...generative
Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis to 2019 for the $6.4 Billion Industry
M2 - Mon Aug 11, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sb3q8w/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019. The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period. In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019. The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Regenerative Medicine (Bone and Joint) Market, by Technology Chapter 5 Regenerative Medicine (Bone and Joint) Market, by Applications Chapter 6 Regenerative Medicine (Bone and Joint) Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Anika Therapeutics, Inc. - Arthrex, Inc. - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew plc - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sb...generative
Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
Business Wire - Mon Aug 04, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 10:30 a.m. ET. The conference is being held at the InterContinental Hotel in Boston, Massachusetts.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIKA THERAPEUTICS
at Investor's Business Daily - Wed Jul 30, 6:03PM CDT
ANIKA THERAPEUTICS (ANIK), a bone-healing product maker, said Q2 EPS rose 50% to 60 cents, beating by 3 cents. Sales increased 26% to $26.3 mil, but missed views for $28.2 mil. Shares fell 6.5% to 46.50.
Anika Therapeutics Reports Second-Quarter 2014 Financial Results
Business Wire - Wed Jul 30, 3:05PM CDT
--Commercial Launch of Monovisc(R) Generates $5 Million Milestone Payment
Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix(R) with Wound Care Leader Medline Industries, Inc.
Business Wire - Wed Jul 30, 12:04PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company's advanced wound care product - Hyalomatrix(R), in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix(R) is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.
Anika Therapeutics Up 36.4% Since SmarTrend Uptrend Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 28, 5:06PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.67. In approximately 5 months, Anika Therapeutics has returned 36.35% as of today's recent price of $47.28.
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019
M2 - Mon Jul 21, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ct2qw/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019" report to their offering. Hyaluronic acid (HA) is a glycosaminoglycan that helps in transportation of nutrients through the body and facilitate water retention in body tissue. It is naturally found in body - in joints, eye cavity, immune system and others. HA was observed to be an important component of articular cartilage where it is present in the form of a coat around each chondrocyte. This report studies the global hyaluronic acid products market by types of products, applications and the major geographic markets. Products market is segmented as single-injection, three-injection cycle and five-injection cycle. Similarly, applications market is segmented as osteoarthritis, ophthalmic surgery, dermal fillers and vesicoureteral reflux (VUR). The market overview section of the hyaluronic acid products market report discusses the market dynamics with respect to market drivers, restraints and opportunities. This section also covers market attractiveness analysis (by geography) and Porter's five forces analysis for the global hyaluronic acid products market. Market share (%) for the major players operating in this market has also been provided for the year 2012, followed by a list of recommendations for the existing and new players to enter and enhance their market shares. The report concludes with the company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. The global hyaluronic acid products market is segmented as follows: Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Hyaluronic Acid Products Market, by Products Chapter 5 Global Hyaluronic Acid Products Market, by Applications Chapter 6 Global Hyaluronic Acid Products Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/6c...ronic_acid
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
